COMMUNIQUÉS West-GlobeNewswire

Nxera Pharma Enters New Commercial Partnership with Shionogi for QUVIVIQ™ in Japan

01/10/2024 - 08:02

QUVIVIQ™ is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co [...]

Vivoryon Therapeutics N.V. Shares Highlights from Virtual Kidney Disease KOL Event

01/10/2024 - 07:00

Halle (Saale) / Munich, Germany, October 1, 2024 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company focused on the discovery and development of small molecule [...]

Santhera Announces Positive Topline Results from LIONHEART Study with AGAMREE® (vamorolone) Demonstrating Unique Mineralocorticoid Receptor Antagonism

01/10/2024 - 07:00

Pratteln, Switzerland, October 1, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the positive outcome of the LIONHEART study, confirming vamorolone’s distinctive action also as a mineralocorticoid receptor [...]

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/10/2024 - 06:05

SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target [...]

LeaderMed Group and Combiphar Form Joint Venture on LM-008, a Novel GLP-1 Dual Agonist, Targeting Indonesia's High Diabetes and/or Obesity Prevalence

01/10/2024 - 04:00

JAKARTA, Indonesia and NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- LeaderMed Group (LeaderMed), a global pharmaceutical development company, and Combiphar, a leading Indonesian pharmaceutical company in Southeast Asia [...]

“Teens for Education and Advocacy on Misophonia” (TEAM) Launches Nation’s First Non-Profit Organization Specifically for Teenagers Tuesday, October 1, 2024 1:11 AM

01/10/2024 - 03:18

Group aims to help shed light on a debilitating and misunderstood condition BREA, CA, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Misophonia is a condition that has exploded in awareness in recent years, yet little is known [...]

CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP

01/10/2024 - 01:07

Patient Special Access Program continues during Health Canada review MELBOURNE, Australia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- CLINUVEL has filed a New Drug Submission (NDS) to Health Canada, seeking approval for its [...]

Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology

01/10/2024 - 00:30

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today [...]

SEQUANA MEDICAL ANNOUNCES CONVERTIBLE FINANCING OF UP TO EUR 6.1 MILLION FROM MAJOR SHAREHOLDERS

30/09/2024 - 23:55

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW [...]

Sequana Medical announces H1 2024 results and provides business update

30/09/2024 - 23:55

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 30 September 2024, 23:55 CEST Sequana Medical announces H1 2024 results and provides business update alfapump ® - US FDA approval anticipated Q1 2025 and US [...]

Yomi Robotic Dental Implant System Drives Increased Implant Volume and Practice Profitability According to Growth Study

30/09/2024 - 23:17

Dental Economics publishes study by leading Missouri dentist Dr. Jonathan Ehlers on how dental practices are increasing implant volume, efficiency, and profitability by offering robot-guided implant placement. MIAMI, [...]

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

30/09/2024 - 23:15

Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life- [...]

Thrive Bioscience Welcomes Christiaan Erik Engstrom as Chief Operating Officer and VP of Corporate Development and Finance

30/09/2024 - 23:11

BEVERLY, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Thrive Bioscience, Inc., a Boston-based manufacturer of instruments for advanced imaging, analytics, and automation for cell-based research and the delivery of medicine [...]

Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

30/09/2024 - 22:45

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on September 30, 2024 it granted stock options to purchase an aggregate of 120,000 shares of [...]

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

30/09/2024 - 22:30

TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on [...]

Umoja Biopharma Announces Oral Presentation at the American College of Rheumatology Convergence 2024

30/09/2024 - 22:30

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR-T cell therapies [...]

Precision Optics Reports Fourth Quarter and Fiscal Year 2024 Financial Results

30/09/2024 - 22:30

Conference Call Scheduled for today, September 30, 2024, at 5:00pm ET. GARDNER, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of [...]

Vaxart Announces Initiation of Sentinel Cohort for Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

30/09/2024 - 22:12

— 400 subject sentinel portion of Phase 2b study will evaluate the safety, immunogenicity and efficacy of Vaxart’s next generation oral pill COVID-19 vaccine compared to an approved mRNA vaccine comparator — — The [...]

Biocodex Microbiota Foundation Invites Canadian Academics and Scientists to Apply for €25,000 Research Grant to Advance Microbiota’s role Study in health and diseases

30/09/2024 - 22:09

MONTREAL, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The Biocodex Microbiota Foundation , an organization founded by Biocodex and dedicated to inspiring scientific projects that explore the microbiome, is calling for grant [...]